WARMINSTER, Pa. — August 6, 2025 — Leads & Copy — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its second quarter 2025 financial results, highlighted by a total revenue of $10.7 million, which includes previously-deferred revenue from the reacquisition of Greater China rights to imdusiran. The company also announced the appointment of Dr. Roger Sawhney to its Board of Directors, succeeding Anuj Hasija, and Dr. Harry Janssen to its Scientific Advisory Board.
According to Arbutus President and CEO Lindsay Androski, the company delivered a strong quarter due to the conclusion of their Greater China partnership with Qilu, regaining global rights for imdusiran, and launching a Scientific Advisory Board focused on late-stage clinical trials.
In addition to the corporate updates, Arbutus is actively supporting its licensee, Genevant Sciences, in ongoing lawsuits against Moderna and Pfizer/BioNTech, seeking compensation for the use of Arbutus’s patented LNP technology in their COVID-19 vaccines.
Financially, Arbutus reported cash, cash equivalents, and marketable securities of $98.1 million as of June 30, 2025. The company’s net income for the quarter was $2.5 million, compared to a net loss of $19.8 million for the same period in 2024.
Dr. Harry L.A. Janssen, MD, PhD, joined the Company’s Scientific Advisory Board effective August 1, 2025, increasing the membership to six global experts in cHBV treatment. Effective August 4, 2025, Anuj Hasija resigned from the Company’s Board of Directors due to his transition to a full-time executive role that precludes his participation on the Arbutus and other boards of directors. Filling the vacancy on our Board of Directors, Dr. Roger Sawhney, MD, joined the Board effective August 4, 2025.
Contact:
Arbutus Biopharma Corporation
ir@arbutusbio.com
Source: Arbutus Biopharma
